CLDX

NASDAQ · Biotechnology

Celldex Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$29.04

-1.06 (-3.52%)

As of Nov 7, 1:48 AM ET ·

CLDX News1 articles

Celldex Shares Pull Back After Barzolvolimab Enrollment Milestone

Celldex Therapeutics shares retreated about 4% in premarket trading Thursday, giving back some of the prior session's 24% surge. The biotech completed patient enrollment for two key Phase 3 studies of its mast cell inhibitor barzolvolimab six months early.